Poolbeg Pharma (LON:POLB) Earns “House Stock” Rating from Shore Capital Group

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reaffirmed by equities researchers at Shore Capital Group in a research note issued to investors on Thursday, Marketbeat reports.

Poolbeg Pharma Stock Down 10.1%

Poolbeg Pharma stock opened at GBX 7.10 on Thursday. The stock has a market cap of £54.20 million, a P/E ratio of -7.55 and a beta of 1.83. Poolbeg Pharma has a twelve month low of GBX 3.30 and a twelve month high of GBX 9.30. The company’s 50-day moving average price is GBX 7.99 and its two-hundred day moving average price is GBX 6.38.

Key Stories Impacting Poolbeg Pharma

Here are the key news stories impacting Poolbeg Pharma this week:

• Positive Sentiment: An interim review of the POLB 001 TOPICAL trial was positive, and the study will continue without changes. The update indicates no safety-related reason to pause, modify or terminate the trial, reducing a key near-term clinical risk. Interim data from POLB 001 TOPICAL clinical trial
• Positive Sentiment: The trial concerns POLB 001 as a potential preventative treatment for cytokine release syndrome, a complication associated with certain cancer therapies. Continued clinical progress supports Poolbeg’s development strategy and may improve the prospect of further trial milestones. Positive interim safety review
• Positive Sentiment: Cavendish reportedly maintained a bullish outlook and a 19p target, arguing that the trial’s progress strengthens its investment case. Shore Capital also reaffirmed its “house stock” rating. Trial progress strengthens Cavendish case
• Neutral Sentiment: The announcement is primarily a safety and continuation update rather than definitive evidence of treatment efficacy. Investors may therefore continue to await further clinical data and subsequent development milestones before assigning substantially greater value to POLB 001.
• Neutral Sentiment: The very high trading volume indicates heightened attention to the announcement, but the share-price decrease suggests that some investors may have been seeking stronger efficacy data or taking profits after the recent run-up.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.